Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with K i s of 0.03 nM, 0.1 nM and 0.02 nM for Pim1 , Pim2 and Pim3 , respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma
In Vitro
GDC-0339 is cytostatic, with an IC 50 of 0.1 μM for MM.1S cells. GDC-0339 treatment reveals a constellation of Pim downstream signaling events consistent with inhibition of Pim kinases. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MM.1S cells Concentration: Incubation Time: 3 days Result: Inhibited cell viability. Western Blot AnalysisCell Line: MM.1S cells Concentration: 0.01 μM, 0.03 μM, 0.09 μM,0.27 μM, 0.83 μM, 2.5 μM Incubation Time: 4 hours Result: Induced a constellation of Pim downstream signaling events consistent with inhibition of Pim kinases.
In Vivo
GDC-0339 (1-300 mg/kg; p.o; daily; for 21 days) is efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models. GDC-0339 has a half-life of t1/2=0.9 h. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C.B-17 SCID mice, RPMI8226 human multiple myeloma xenograft mouse modelDosage: 1mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg, 300 mg/kg Administration: Oral administration; once daily; for 21 days Result: Showed dose-dependent tumor growth inhibition.
Form:Solid
IC50& Target:Ki: 0.03 nM (Pim1), 0.1 nM (Pim2), 0.02 nM (Pim3)
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Klasse | Azoles |
| Subclass | Thiazoles |
| Intermediate Tree Nodes | Thiazolecarboxylic acids and derivatives |
| Direct Parent | Thiazolecarboxamides |
| Alternative Parents | 2,4,5-trisubstituted thiazoles 2-heteroaryl carboxamides Dialkylarylamines Azepanes Fluorobenzenes Aminothiazoles Aryl fluorides Heteroaromatic compounds Pyrazoles Vinylogous amides Secondary carboxylic acid amides Amino acids and derivatives Azacyclic compounds Hydrocarbon derivatives Organofluorides Organooxygen compounds Alkyl fluorides Monoalkylamines Organic oxides |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | 2-heteroaryl carboxamide - 2,4,5-trisubstituted 1,3-thiazole - Dialkylarylamine - Thiazolecarboxamide - Azepane - Fluorobenzene - Halobenzene - 1,3-thiazolamine - Aryl fluoride - Aryl halide - Monocyclic benzene moiety - Benzenoid - Heteroaromatic compound - Vinylogous amide - Pyrazole - Amino acid or derivatives - Carboxamide group - Secondary carboxylic acid amide - Azacycle - Carboxylic acid derivative - Alkyl halide - Alkyl fluoride - Primary aliphatic amine - Organohalogen compound - Organofluoride - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Organonitrogen compound - Amine - Organooxygen compound - Primary amine - Aromatic heteromonocyclic compound |
| Beschreibung | This compound belongs to the class of organic compounds known as thiazolecarboxamides. These are heterocyclic compounds containing a thiazole ring which bears a carboxylic acid amide group. |
| External Descriptors | Not available |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Löslichkeit | DMSO : ≥ 52 mg/mL (111.71 mM) |
|---|---|
| Molekulargewicht | 465.500 g/mol |
| XLogP3 | 3.000 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 4 |
| Exact Mass | 465.156 Da |
| Monoisotopic Mass | 465.156 Da |
| Topological Polar Surface Area | 143.000 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 657.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Item-specific validated applications and conditions
General starting points for small-molecule screening (not item-specific)
These are general templates. Optimize parameters upon obtaining compound-specific data from the CoA or preliminary experiments.
Item-specific biological function/target
General notes for small-molecule research tools (not item-specific)
Documentation and controls
Note: This product is for research use only; no clinical or diagnostic claims are made or implied.
This section is generally not directly applicable to a discrete small-molecule screening compound lacking acid/base specification or buffering capacity.
Item-specific buffer usage
General guidance for preparing assay solutions (not item-specific)
Since no pKa or buffer-related data are provided for this item, rely on general assay buffer best practices and confirm compatibility empirically.
This section discusses greener options for solvents and processes used with small-molecule screening compounds in general; item-specific green metrics for GDC-0339 are not available.
Solvent considerations (general)
Process and handling
Small comparison (general; not item-specific)
Waste management
No pharmacopeial status, excipient role, or formulation-specific information is provided for this item.
Item-specific statements
General considerations for pre-formulation research (not item-specific)
No medical or clinical claims are made or implied for this product.
Item-specific properties
Storage and shipping (from Product Data)
General/literature guidance for small-molecule screening solids (not item-specific)
Item-specific (from Product Data)
What to expect in CoA/Spec Sheet for small-molecule library members (general guidance)
Interpreting common grades (general definitions; not item-specific)
Practical tips
Item-specific applications
General research context for small-molecule library members (not item-specific)
Practical assay tips
Documentation
Item-specific reaction conditions cannot be provided due to absent structural information.
General guidance for handling unknown or unspecified small molecules in lab operations (not item-specific)
These are general best practices and not product specifications. Tailor conditions once the structure and properties are confirmed.
Safety information provided for this item is limited.
Item-specific (from Product Data)
Practical laboratory precautions (general guidance for small molecules; defer to SDS for this product)
Always consult the product-specific SDS and CoA for authoritative hazard, toxicological, and disposal information before use.
Item-specific solvent data
General strategy for dissolving small-molecule screening compounds (not item-specific)
Selection considerations
Documentation
Item-specific (from Product Data)
Reconstitution (general guidance for small-molecule solids; not item-specific)
Stability and handling
For definitive instructions (including any item-specific solubility, stability, or reconstitution notes), consult the batch CoA and SDS.
Brief overview: GDC-0339 is listed as a small-molecule screening compound; however, structural identifiers are not provided in the current Product Data.
Item-specific (from Product Data)
Structural features
General guidance (chemistry data handling)
Item-specific synthetic roles
General considerations (not item-specific)
Intellectual property and provenance
To plan synthetic work or analog preparation, obtain the full structure (SMILES/InChI) and confirm the exact salt/solvate form from the CoA.
Item-specific target/biomolecule specificity
General guidance (not item-specific)
Only target specificity supported by the item’s CoA/technical note should be cited in publications.